Oral: 10–120 mg daily IV: 40 mg once daily for up to 5 days Patients with recent bleeding on endoscopy: 80 mg stat followed by 8 mg/hour for 72 hours (British Society of Gastroenterology)
20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function
HD                     :Not dialysed. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anticoagulants: effect of coumarins possibly enhanced
Anti-epileptics: effects of phenytoin possibly enhanced
Antivirals: reduced atazanavir concentration – avoid concomitant use; AUC of saquinavir increased by 82% (increased risk of toxicity)
Ciclosporin: variable response; mostly increase in ciclosporin levelCilostazol: increased cilostazol concentration – avoid concomitant use
Tacrolimus: may increase tacrolimus concentration
ADMINISTRATION
Reconstition
5 mL solvent provided per 40 mg vial
Route
Oral, IV
Rate of Administration
Bolus: over 5 minutes Infusion: 40 mg over 20–30 minutes Continuous infusion: 8 mg/hour
Comments
Add to 100 mL sodium chloride 0.9% or glucose 5%Once diluted stable for 12 hours in sodium chloride 0.9% and 3 hours in glucose 5%Use oral as soon as possible 200 mg in 50 mL for 8 mg/hour infusion. (UK Critical Care Group, Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006)
OTHER INFORMATION
Omeprazole clearance is not limited by renal disease.